LNSR
LENSAR, Inc.
NASDAQ · Healthcare · Medical - Devices · US
$5.75
−0.86%Year over year
Reported trailing growth
- Revenue
- +3.3%
- EBITDA
- +233.3%
- EBIT
- +43.5%
- EPS
- +130.2%
- Free cash flow
- -40.1%
- Operating cash flow
- -42.3%
Forward estimates
Based on analyst estimates
- Revenue
- +17.5%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +18.2%
- EBITDA
- —
- EBIT
- —
- Net income
- -9.2%
- EPS
- -5.1%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026